New antidepressants: Use in high-risk patients

A. S. Hale, B. E. Leonard, P. E. Stokes, J. F. Greden, G. D. Tollefson, A. C. Altamura

Research output: Contribution to journalArticle

Abstract

This paper will review evidence on the safety and efficacy of new antidepressants in high-risk patients. Where available, data will be reviewed on the serotonin selective reuptake inhibitors (SSRIs), including fluoxetine, fluvoxamine, paroxetine, sertraline, and citalopram, and on the new reversible inhibitor of monoamine oxidase-A moclobemide.

Original languageEnglish
Pages (from-to)61-70
Number of pages10
JournalJournal of Clinical Psychiatry
Volume54
Issue number8 SUPPL.
Publication statusPublished - 1993

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Fingerprint Dive into the research topics of 'New antidepressants: Use in high-risk patients'. Together they form a unique fingerprint.

  • Cite this

    Hale, A. S., Leonard, B. E., Stokes, P. E., Greden, J. F., Tollefson, G. D., & Altamura, A. C. (1993). New antidepressants: Use in high-risk patients. Journal of Clinical Psychiatry, 54(8 SUPPL.), 61-70.